Financial Performance - The company's revenue for Q1 2025 was approximately ¥500.59 million, representing a year-over-year increase of 31.46% compared to ¥380.80 million in the same period last year[8]. - The net profit attributable to shareholders was a loss of approximately ¥234.88 million, an improvement from a loss of ¥283.03 million in the previous year[8]. - Total operating revenue for Q1 2025 reached ¥500,591,459.94, a 31.5% increase from ¥380,804,271.07 in Q1 2024[22]. - Net loss for Q1 2025 was ¥259,586,438.78, an improvement from a net loss of ¥299,647,965.46 in Q1 2024[22][23]. - Basic and diluted earnings per share for Q1 2025 were both -¥0.24, compared to -¥0.29 in Q1 2024[23]. Research and Development - Research and development expenses totaled approximately ¥350.58 million, accounting for 70.03% of the revenue, a decrease of 2.52 percentage points from the previous year[8]. - R&D expenses rose significantly to ¥350,575,453.92 in Q1 2025, compared to ¥276,292,124.92 in Q1 2024, marking a 27% increase[22]. - The company plans to accelerate the launch of multiple key registration clinical trials for early-stage pipelines by 2025, aiming to sustain revenue growth[17]. - The company has received approvals for clinical trial applications for JS212 and JS213, indicating ongoing development in its pipeline[17]. Cash Flow and Liquidity - The net cash flow from operating activities was a negative ¥24.33 million, an improvement from a negative ¥376.58 million in the same period last year[8]. - Cash flow from operating activities increased to ¥740,358,831.82 in Q1 2025, compared to ¥396,310,961.15 in Q1 2024, representing an increase of 86.7%[25]. - The company reported a significant increase in cash received from operating activities, indicating improved liquidity and operational efficiency[25]. - The ending cash and cash equivalents balance was $2.51 billion, down from $4.55 billion in the previous period[26]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥10.90 billion, a slight increase of 1.07% from ¥10.78 billion at the end of the previous year[9]. - The total assets as of the latest reporting period amounted to ¥10,897,069,766.80, up from ¥10,781,960,410.10[20]. - Total liabilities increased to ¥5,227,909,703.20, compared to ¥4,849,830,645.95 in the previous period, reflecting a rise of 7.8%[20]. - The total equity attributable to shareholders decreased to ¥5,620,244,628.63 from ¥5,860,424,336.29, a decline of 4.1%[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,429[12]. - The total number of ordinary shareholders as of the reporting period was 29,429, with 29,420 being A-share ordinary shareholders[15]. - The top shareholder, HKSCC Nominees Limited, held 22.25% of the shares, totaling approximately 219.29 million shares[13]. Market and Product Development - The company plans to continue focusing on the commercialization of its pharmaceutical products to drive future revenue growth[11]. - The company's revenue growth was primarily driven by the sales of its core product, Toripalimab injection, which achieved sales revenue of approximately RMB 447 million, representing a year-on-year increase of about 45.72%[15]. - Toripalimab has been approved for 12 indications in mainland China, with 10 of these included in the national medical insurance catalog, enhancing its market accessibility[16]. - The company is focusing on enhancing its commercialization competitiveness through continuous global market expansion and operational management improvements[17].

Financial Performance - For the year ended December 31, 2024, the total revenue of the group was approximately RMB 1,948 million, an increase of about 30% compared to the same period in 2023, primarily due to increased pharmaceutical sales, with core product Tuoyi® (Tremelimumab) domestic sales revenue reaching approximately RMB 1,501 million, a 66% increase year-on-year[7]. - The loss attributable to owners of the company decreased to approximately RMB 1,282 million, a reduction of about RMB 999 million or approximately 44% compared to the same period in 2023[8]. - Total revenue for 2024 reached RMB 1.948 billion, representing a year-on-year increase of approximately 30%[16]. - Core product Tuoyi® contributed RMB 1.501 billion in domestic sales, a year-on-year growth of 66%[16]. - The company achieved a significant reduction in net loss attributable to shareholders, with losses narrowing to RMB 2.356 billion in 2023 from RMB 2.582 billion in 2022[13]. - The company’s total comprehensive expenses for 2023 were RMB 2.608 billion, a slight decrease from RMB 2.651 billion in 2022[15]. - The company reported a basic loss per share of RMB (1,282,398) thousand for the year ended December 31, 2024, compared to RMB (2,281,624) thousand for the year ended December 31, 2023[119]. Research and Development - The total R&D expenditure for the reporting period was approximately RMB 1,275 million, a decrease of about 34% compared to 2023, mainly due to the implementation of cost control policies and optimization of resource allocation[8]. - The company has expanded its innovative R&D pipeline to include over 30 drugs in clinical trials and more than 20 drugs in preclinical development across five major therapeutic areas[9]. - The company is advancing its clinical pipeline with key products like Tifcemalimab and JS207, with Tifcemalimab undergoing two Phase III clinical trials[19]. - The company has conducted 92 clinical studies in 2024, enrolling over 2,100 participants, demonstrating increased clinical research efficiency[25]. - The company is actively pursuing new product development and market expansion strategies to strengthen its competitive position in the industry[160]. - The company is committed to increasing its innovation capabilities and accelerating the clinical trial and commercialization processes of new drugs[150]. Product Approvals and Market Expansion - The FDA approved the drug LOQTORZI® for the treatment of nasopharyngeal carcinoma in October 2023, marking it as the first drug of its kind in the U.S.[9]. - The company received NMPA approval for the sNDA of its drug in combination with other treatments for various cancers, including advanced liver cancer and triple-negative breast cancer, in 2024[10]. - The company’s drug LOQTORZI® has been approved in multiple countries, including India and Jordan, for treating nasopharyngeal carcinoma[10]. - The company’s drug Tuo Yi® has been included in the national medical insurance catalog for all 10 approved indications in mainland China, making it the only PD-1 monoclonal antibody for certain cancer treatments[11]. - The company has initiated commercial sales of Tuoyi® in the US and India, expanding its global market presence[17]. - Trelipilumab (LOQTORZI®) received FDA approval in October 2023 and will officially launch in the U.S. market in January 2024, becoming the only recommended first-line treatment for recurrent/metastatic nasopharyngeal carcinoma in the NCCN guidelines[31]. Financial Position and Liquidity - As of December 31, 2024, the group had a total cash and cash equivalents balance of approximately RMB 2,917 million, indicating a relatively strong liquidity position to support future development[8]. - The company has a cash and financial product balance of approximately RMB 2,917 million, indicating sufficient funding reserves[25]. - The company’s total assets amounted to RMB 11.362 billion as of December 31, 2023, while total liabilities reached RMB 4.022 billion[13]. - The company’s net asset value was RMB 7.340 billion as of December 31, 2023, down from RMB 9.794 billion in 2022[13]. - The company has incurred a net cash outflow of approximately RMB 1,443 million during the reporting period[148]. - The company expects to secure a credit facility of up to RMB 8,000 million to support its operations and project development, effective from the approval date of the 2024 annual general meeting until the 2025 annual general meeting[138]. Corporate Governance - The company has established a governance framework based on the corporate governance code outlined in the Stock Exchange Listing Rules[187]. - The board believes that the company has complied with all applicable principles and code provisions of the corporate governance code during the reporting period[188]. - The company has implemented a series of policies and processes to improve the board's governance capabilities[187]. - The board consists of 14 members, including 8 executive directors, 1 non-executive director, and 5 independent non-executive directors[193]. - The board has maintained compliance with listing rules by having at least three independent non-executive directors, representing over one-third of the board[198]. - The company has a strong leadership team with extensive experience in the pharmaceutical and medical fields, enhancing its strategic direction and operational efficiency[160]. Employee and Operational Efficiency - The company has 2,578 employees, with 620 dedicated to drug research and development, maintaining a gender balance with approximately 52% female employees[43]. - The company emphasizes employee career development through a unified performance management system and provides training resources to support professional growth[44]. - The company has optimized its commercialization team structure, significantly improving execution and sales efficiency[56]. - The company is focused on strategic research to mitigate risks associated with new drug development and will discontinue projects that do not meet expected outcomes[146]. Market Risks and Challenges - The company is at risk of not achieving profitability in the short term due to ongoing R&D investments and operational costs[144]. - The company faces potential financial risks from currency fluctuations, particularly related to assets and liabilities denominated in HKD and USD[148]. - The company is exposed to risks related to supply chain stability and potential disruptions in raw material supply[147]. - The company acknowledges the impact of macroeconomic factors, including uncertainties in international trade relations, on its overseas operations[151].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 財務摘要 1 • 截至2024年12月31日，報告期內本集團收入總額約人民幣1,948百萬元，較 2023年同期增加約30%，主要由於藥品收入的增加，其中：核心產品拓益® （特瑞普利單抗）國內銷售收入約為人民幣1,501百萬元，較2023年同期增加 約66%。 • 報告期內本集團研發開支總額約人民幣1,275百萬元，較2023年同期減少約 34%。研發開支減少主要由於本集團實施成本控制政策，努力優化資源配 置，聚焦於更有潛力的研發管綫。此外，核心產品拓益®的多項臨床試驗相 繼達到主要研究終點亦促進研發開支自然下降。 • 報告期內本公司擁有人應佔虧損減少至人民幣1,282百萬元，較2023年同期 減少約人民幣999百萬元或約44%。 • 截至2024年12月31日，本集團銀行結餘及現金和金融產品餘額合計約人民 幣2,917百萬元，資金狀況相對充裕，可支持本集團的發展。 業務摘要 SHANGHAI JUNS ...

Financial Performance - The company's revenue for Q3 2024 reached ¥485,143,734.52, representing a 53.16% increase compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was -¥281,813,873.94, with a year-to-date net profit of -¥926,768,557.18[3]. - The company's revenue for the first three quarters of 2024 reached approximately RMB 1.27 billion, representing a year-on-year increase of about 29% compared to RMB 986.46 million in the same period of 2023[15]. - Total revenue from sales of goods and services for the first three quarters of 2024 was ¥1,334,950,275.33, up from ¥994,903,657.69 in the same period of 2023, reflecting a growth of 34.3%[19]. - The company reported a total comprehensive loss of -¥1,036,670,389.84 for Q3 2024, compared to -¥1,605,861,657.78 in Q3 2023, marking a 35.3% reduction in comprehensive losses[18]. - The net profit for Q3 2024 was -¥988,725,690.94, an improvement from -¥1,555,128,891.35 in Q3 2023, representing a 36.4% reduction in losses[18]. - Operating profit for Q3 2024 was -¥969,121,005.27, compared to -¥1,580,362,717.66 in the same period last year, indicating a 38.5% improvement[18]. Research and Development - Research and development (R&D) expenses totaled ¥327,892,775.06 for the quarter, accounting for 67.59% of revenue, a decrease of 34.07 percentage points year-on-year[4]. - The company is focusing on cost control and resource allocation towards high-potential R&D projects, leading to a reduction in losses[13]. - Research and development expenses decreased to ¥874,268,925.53 from ¥1,270,626,649.07, a reduction of approximately 31.1% year-over-year[18]. - The company plans to accelerate the development and application for late-stage pipelines, including anti-tumor monoclonal antibodies and other innovative drugs[13]. - The company has received regulatory approval for the launch of the anti-PCSK9 monoclonal antibody, which is expected to enhance its product portfolio[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,498[8]. - The total number of ordinary shareholders reached 29,489 as of the end of the reporting period[10]. - The top 10 shareholders hold a total of 38,594,237 shares, representing 3.92% of the total shares[11]. - HKSCC NOMINEES LIMITED is the largest shareholder with 219,291,210 shares, accounting for 22.25%[9]. - The company has no shareholders participating in margin trading or securities lending as of the reporting period[10]. - The shareholding structure indicates that 熊俊 and 熊凤祥 are the controlling shareholders, with 熊俊 being the actual controller[10]. - The top 10 unrestricted circulating shareholders collectively hold 42,112,468 shares, which is 4.27% of the total shares[11]. - There were no changes in the top 10 shareholders due to securities lending or borrowing activities compared to the previous period[12]. Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥1,113,472,084.61 year-to-date[3]. - Cash flow from operating activities showed a net outflow of -¥1,113,472,084.61, an improvement from -¥1,664,114,192.65 in Q3 2023[20]. - The company reported a total cash and cash equivalents balance of RMB 3.045 billion, indicating a strong liquidity position[13]. - The cash and cash equivalents at the end of Q3 2024 were ¥2,474,334,261.64, down from ¥4,141,718,242.77 at the end of Q3 2023[20]. - The company's investment activities resulted in a net cash outflow of -¥1,083,510,749.67 for Q3 2024, compared to -¥653,834,246.14 in Q3 2023, reflecting increased investment activities[20]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥10,857,613,524.70, down 4.28% from the previous year[4]. - The total liabilities as of September 30, 2024, amounted to RMB 4.578 billion, an increase from RMB 4.022 billion at the end of 2023[15]. - The weighted average return on net assets was -4.45%, an increase of 0.46 percentage points compared to the previous year[4]. Future Outlook - The report does not provide specific future outlook or performance guidance[12]. - The company has not disclosed any new product or technology developments in this report[12]. - The company achieved significant milestones in clinical trials for its core product, Tuoyi®, contributing to improved revenue performance[7].

Financial Performance - For the six months ended June 30, 2024, the total revenue of the group was approximately RMB 786 million, an increase of about 17% compared to the same period in 2023, primarily driven by an 11% increase in pharmaceutical revenue[4]. - The domestic sales revenue of the core product Tuoyi® (Tremelimumab) reached approximately RMB 671 million, representing a significant increase of about 50% compared to the same period in 2023[4]. - In the first half of 2024, the company achieved revenue of RMB 786 million, representing a 17% year-over-year increase[14]. - The core product, Tuoyi® (LOQTORZI®), saw domestic sales revenue grow approximately 50% year-over-year, totaling RMB 671 million[14]. - The company reported a net loss of RMB 688 million for the period, a 39% reduction compared to the loss of RMB 1,125 million in the same period last year[11]. - The company reported a total comprehensive loss of RMB (712,787) thousand for the six months ended June 30, 2024, compared to RMB (1,163,516) thousand for the same period in 2023[177]. - The company incurred a loss of RMB (688,445) thousand during the six months ended June 30, 2024, compared to a loss of RMB (1,125,338) thousand in the same period of 2023[177]. Research and Development - Research and development expenses totaled approximately RMB 546 million, a decrease of about 42% compared to the same period in 2023, due to cost control measures and optimization of resource allocation[4]. - The reduction in R&D expenses is attributed to the completion of major clinical trial endpoints for core products, leading to a natural decline in spending[4]. - The company has expanded its innovative research and development pipeline to include small molecule drugs, peptide drugs, antibody-drug conjugates (ADCs), and nucleic acid drugs, covering five major therapeutic areas[5]. - The product pipeline includes over 30 candidates in clinical trials and more than 20 in preclinical development, covering five major therapeutic areas including oncology and autoimmune diseases[31]. - The company is focused on advancing its pipeline of innovative therapies to address unmet medical needs in oncology[35]. - The company is committed to increasing R&D investments and accelerating the clinical trial and approval processes for innovative drugs to respond to industry and policy risks[150]. Regulatory Approvals and Market Expansion - Three drugs have been included in the new National Medical Insurance Catalogue, with Tuoyi® now covering six indications, including first-line nasopharyngeal carcinoma and first-line non-squamous non-small cell lung cancer[5]. - The company has received regulatory acceptance for multiple new drug applications, including the first-line treatment for advanced nasopharyngeal carcinoma and small cell lung cancer[7]. - As of the report date, Tuoyi® has been approved for 10 indications in mainland China, with two supplemental new drug applications (sNDA) under review[13]. - The company has established commercial partnerships in over 50 countries, including the Middle East, North Africa, and Latin America, to promote the commercialization of Tretinoin monoclonal antibody[20]. - The company is accelerating its internationalization efforts and has made significant progress in innovative therapies and drug commercialization[5]. Financial Position and Cash Flow - As of June 30, 2024, the group had a cash and cash equivalents balance of approximately RMB 3,311 million, a slight decrease of RMB 467 million from December 31, 2023, indicating a relatively ample liquidity position[4]. - The total assets of the company amounted to RMB 11,007 million, a 3% decrease from RMB 11,362 million at the end of the previous year[12]. - The company’s total equity as of June 30, 2024, was RMB 6,623,420 thousand, a decrease from RMB 9,794,250 thousand as of January 1, 2023[177]. - The net cash inflow from financing activities was approximately RMB 739 million, while the net cash outflow from operating activities was approximately RMB 869 million[85]. - The company’s cash flow from financing activities included borrowings of RMB 1,434,544 thousand for the six months ended June 30, 2024, compared to RMB 214,726 thousand in the same period of 2023[180]. Shareholder Structure and Governance - The company has a total of 14 board members, including 8 executive directors, 1 non-executive director, and 5 independent non-executive directors[122]. - The company has established various action agreements, including the 2017 and 2019 action agreements, which consolidate ownership among key stakeholders[129]. - The company continues to maintain a strong governance structure with significant insider ownership, which may influence future strategic decisions and market performance[134]. - The concert party agreements in place influence the perception of shareholdings among related parties, impacting overall governance and control[137]. Clinical Trials and Product Development - The company is currently marketing three drugs (Tuoyi®, Junmai Kang®, and Mindewi®) and has nearly 30 drug candidates in clinical trials, with over 20 in preclinical development[5]. - The company has multiple ongoing clinical trials for various cancer treatments, including non-small cell lung cancer and renal cell carcinoma[35]. - Tifcemalimab is being evaluated in over 30 studies across various cancer types, highlighting its potential as a cornerstone drug in immuno-oncology[56]. - The company has initiated a Phase III clinical trial (NCT06170489) for tifcemalimab combined with teriprizumab in treating cHL, aiming to recruit approximately 185 patients across over 50 centers in China[24]. Risks and Challenges - The company faces risks of not achieving profitability due to high R&D costs and operational expenses, with future earnings dependent on the progress of drug approvals and sales[143]. - The company has a risk of significant performance decline or losses due to ongoing R&D investments and costs associated with new drug registrations and market promotions[144]. - The company is exposed to financial risks related to foreign exchange fluctuations, particularly with assets and liabilities denominated in currencies such as HKD, USD, EUR, and GBP[147].

Investment Rating - The report does not provide a specific investment rating for the company, but it indicates a neutral stance towards the industry, suggesting that the overall return in the next six months will be between -5% and 5% compared to relevant market indices [10]. Core Insights - The company achieved a revenue of 790 million yuan in the first half of 2024, representing a year-on-year growth of 17.4%. However, it reported a net loss attributable to shareholders of 650 million yuan [2]. - The core product, Toripalimab, saw rapid sales growth, with domestic sales reaching 671 million yuan, a year-on-year increase of approximately 50%. The product has been included in the national medical insurance catalog for six indications, making it the only PD-1 monoclonal antibody for melanoma treatment in the catalog [2]. - The company is advancing its internationalization efforts, with Toripalimab receiving FDA approval in October 2023 and being available in the U.S. since January 2024. The application process for multiple indications in other countries is also progressing steadily [2]. Performance Summary - Revenue for the first half of 2024 was 790 million yuan, with a year-on-year growth of 17.4%. The net profit attributable to shareholders was a loss of 650 million yuan [2]. - The sales of Toripalimab are expected to enter a positive cycle, with projected revenue growth rates of 21.5%, 63.2%, and 31.3% for 2024, 2025, and 2026, respectively. The net profit losses are expected to decrease from 1.91 billion yuan in 2024 to 570 million yuan in 2026 [3][4]. Research and Development Progress - The company has completed the first patient enrollment in a multi-center Phase III clinical trial for BTLA monoclonal antibody across China, the U.S., Europe, and Japan. The study is ongoing with continuous patient enrollment [3]. - The R&D pipeline is progressing efficiently, with two supplemental new drug applications (sNDA) for the monoclonal antibody Anlotinib accepted by the NMPA in April 2024 for specific cholesterol-related conditions [3]. - The company is focusing on advancing several early-stage products, including Claudin18.2 ADC, PI3K-α oral small molecule inhibitors, and dual antibodies targeting CD20/CD3 and PD-1/VEGF [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 於本公告中，「我們」指本公司，如文意另有所指，則指本集團。 財務摘要 1 • 截至2024年6月30日，報告期內本集團收入總額約人民幣786百萬元，較 2023年同期增加約17%，主要由於藥品收入較2023年同期增加約11%，其 中：核心產品拓益® （特瑞普利單抗）國內銷售收入約為人民幣671百萬元， 較2023年同期增加約50%。 • 報告期內本集團研發開支總額達約人民幣546百萬元，較2023年同期減少約 42%。研發開支減少主要由於本集團實施成本控制政策，努力優化資源配 置，聚焦於更有潛力的研發管綫。此外，核心產品拓益®的多項臨床試驗相 繼達到主要研究終點亦促進研發開支自然下降。 • 報告期內本公司擁有人應佔虧損減少至人民幣646百萬元，較20 ...

Financial Performance - The company's operating revenue for Q1 2024 was RMB 380,804,271.07, representing a 49.24% increase compared to the same period last year[5] - The net profit attributable to shareholders was a loss of RMB 283,029,082.76, with a net profit excluding non-recurring items of RMB -307,067,930.26[5] - The company reported a weighted average return on net assets of -4.04%, an increase of 1.88 percentage points[5] - Total revenue for Q1 2024 reached ¥380,804,271.07, a significant increase from ¥255,154,522.24 in Q1 2023, representing a growth of approximately 49.2%[18] - Operating profit for Q1 2024 was reported at -¥292,835,633.87, an improvement compared to -¥633,218,295.88 in Q1 2023, indicating a reduction in losses[18] - Net loss for Q1 2024 was -¥299,647,965.46, compared to -¥639,619,944.79 in the same period last year, reflecting a decrease in net losses by about 53%[18] Cash Flow - The net cash flow from operating activities was RMB -376,577,871.82, indicating a significant cash outflow[5] - Cash inflow from operating activities totaled ¥399,332,111.78 in Q1 2024, up from ¥302,002,091.08 in Q1 2023, marking an increase of approximately 32.3%[20] - The net cash flow from operating activities for Q1 2024 was -$376.58 million, an improvement from -$720.25 million in Q1 2023, indicating a 47.7% reduction in cash outflow[21] - The total cash outflow for purchasing goods and services was ¥433,711,376.04 in Q1 2024, down from ¥562,535,881.61 in Q1 2023, reflecting a decrease of approximately 22.9%[20] - The company reported a total cash outflow from operating activities of $775.91 million, down from $1.02 billion in the same quarter last year, reflecting a 24.0% decrease[21] Research and Development - Research and development expenses totaled RMB 276,292,124.92, a decrease of 47.64% year-on-year[5] - The ratio of R&D expenses to operating revenue was 72.55%, down 134.25 percentage points from the previous year[6] - Research and development expenses for Q1 2024 were ¥276,292,124.92, down from ¥527,659,904.54 in Q1 2023, showing a reduction of about 47.6%[18] - The company has reduced losses compared to the same period last year by optimizing resource allocation and focusing on promising R&D pipelines[13] Assets and Liabilities - Total assets increased to RMB 12,024,485,796.49, up 6.01% from the end of the previous year[6] - The total current assets increased to CNY 6.19 billion, compared to CNY 5.57 billion at the end of 2023, reflecting a growth of approximately 11.2%[15] - Total liabilities increased to ¥5,005,671,597.96 in Q1 2024 from ¥4,022,256,399.35 in Q1 2023, representing an increase of approximately 24.5%[16] - The total equity attributable to shareholders decreased to ¥6,866,046,795.72 in Q1 2024 from ¥7,151,224,186.47 in Q1 2023, a decline of about 4%[16] Market and Product Development - The company's revenue from the core product, Toripalimab injection (brand name: Tuoyi®/LOQTORZI™), reached approximately CNY 306.86 million, representing a year-on-year growth of about 56.82%[13] - The company is advancing multiple late-stage pipeline projects, including JS002 (anti-PCSK9 monoclonal antibody) and JS005 (anti-IL-17A monoclonal antibody), to drive future revenue growth[14] - The company has received priority review designation for the marketing application of Toripalimab in Singapore for specific cancer treatments[13] - The number of indications for Toripalimab included in the national medical insurance directory has increased to 6, enhancing its market accessibility[13] - The company has established commercial partnerships in over 50 countries for Toripalimab, indicating strong international market expansion efforts[13] Inventory and Cash Management - The total inventory as of March 31, 2024, was CNY 535.55 million, slightly down from CNY 538.05 million at the end of 2023[15] - The company reported cash and cash equivalents of CNY 4.56 billion, up from CNY 3.79 billion in the previous quarter[15] - The total cash and cash equivalents at the end of Q1 2024 amounted to $4.55 billion, a decrease from $4.98 billion at the end of Q1 2023[21] - Cash received from borrowings in Q1 2024 was $1.28 billion, a substantial increase from $91.30 million in Q1 2023[21]

上海君實生物醫藥科技股份有限公司 Shanghai Junshi Biosciences Co., Ltd.* (於中華人民共和國註冊成立的股份有限公司) 股份代號: 1877 ...

[ 2T 0a 2b 4le 年_S 0t 3oc 月kIn 29fo 日] 证券研究报告•2023年报点评 当前价： 9.87港元 君实生物（1877.HK） 医疗保健 目标价： ——港元 PD-1 单抗获 FDA 批准上市，在研管线加速推进 投资要点 西南证券研究发展中心 [T a业ble绩_S总u结m：ma公ry司] 2023年度实现营业收入15.03亿元（同比增长3.38%），实现 [分Ta析bl师e_：Au杜th向or阳] 归母净利润-22.83亿元（同比减亏1.05亿元），扣非归母净利润-22.98亿元（同 执业证号：S1250520030002 比减亏1.53亿元）。 电话：021-68416017 邮箱：duxy@swsc.com.cn  首款获FDA批准的国产PD-1单抗，新增3项适应症纳入医保。2023 年 10 月， 特瑞普利单抗联合顺铂/吉西他滨作为转移性或复发性局部晚期鼻咽癌成人患者 [相Tab对le指_Q数u表ot现eP ic] 的一线治疗，以及作为单药治疗既往含铂治疗过程中或治疗后疾病进展的复发 性、不可切除或转移性鼻咽癌的成人患者的BLA获得 FDA批准，特瑞普利单抗 君实 ...